Please assess the completion status of the following clinical trial:

Trial Title: Uncovering Neural and Immune Mechanisms of Chronic Pain in Post Treatment Lyme Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. History of Lyme Disease and treatment:~2. Current chronic pain in the musculoskeletal system~3. clinically troubling sensory hypersensitivity (e.g., light or touch)~4. Able to speak and read English~5. Willing to not take other than study centrally acting pharmacologic agents prior to MRI and for the duration of treatment with study medications~Exclusion Criteria:~1. Diagnosis of another (not LYME) general medical condition that has a major role in the onset, severity, exacerbation or maintenance of pain, or sensory hypersensitivity.~2. DSM-IV Axis I lifetime diagnosis of Pervasive Developmental Disorder, Autism, Psychotic disorder, Bipolar Disorder, Substance dependence.~3. I current diagnosis of Major Depressive Disorder or substance abuse~4. History of head injury with loss of consciousness (\>5min), neurologic disease, seizures (excluding febrile seizures) or serious unstable medical condition (e.g. cancer, diabetes)~5. Current or recent (last month) opiate use~6. For 2 weeks prior to MRI and diagnostic visit, unable to be free of centrally active medications or treatment methods. These include medications commonly used to treat pain (eg, antidepressants, muscle relaxants, centrallyacting analgesics), as well as transcutaneous electrical nerve stimulation, biofeedback, tender and trigger point injections, acupuncture, and anesthetic or narcotic patches. PRN doses of short acting medications, e.g. acetaminophen, aspirin, and nonsteroidal antiinflammatory agents will be allowed for pain with usage carefully monitored, but patients must be willing to be off of these medications for 24 hours prior to the major evaluations at intake and MRI study visit. Stable doses of non-benzodiazepines will be allowed for sleep (but not tricyclics)~7. Ferromagnetic implants (e.g. pacemaker, etc.)~8. Metal Braces or Retainers~9. Transdermal medicinal patches that cannot be removed~10. Birth at \< 37 weeks gestational age (prior studies have shown dramatic effects on brain structure and function in prematurely born children)~11. Claustrophobia~12. Women will be excluded if they are pregnant, lactating, or not either surgically-sterile or using appropriate methods of birth control. Women must agree to continue using applicable birth control throughout the trial. All women of child-bearing potential must have a negative pregnancy test at the intake visit.~13. Inability to reliably rate intensity of pain in response to a fixed thermal stimulus~14. Inability to tolerate sound intensity of fMRI~15. Individuals currently successfully treated by medications for their pain.~16. History of inability to tolerate treatment with SSRI or SNRI medications or d-cycloserine; or medication induced mania~17. Renal insufficiency or congestive heart failure~18. Hepatic malfunction Liver Test

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Milnacipran augmented by D-cycloserine (Type: ACTIVE_COMPARATOR): participants will be receiving Milnacipran for 12 weeks. During weeks 6-12 participants will be receiving D-cycloserine in addition to Milnacipran
- Milnacipran augmented by Placebo (Type: PLACEBO_COMPARATOR): participants will be receiving Milnacipran for 12 weeks. During weeks 6-12 participants will be receiving placebo in addition to Milnacipran

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues